TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22495183
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily administration)
Study: 16416004
Drug: Interferon-alpha alone
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha alone for 1 month followed by 5 months of continuous treatment with interferon-alpha (treatment group A)
Study: 16416004
Drug: Interferon-alpha combined
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha combined with thymosin-alpha1 for 1 month followed by 5 months of continuous treatment with interferon-alpha and thymosin-alpha1 (treatment group B)
Study: 16416004
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiviral drug after lamivudine withdrawal)
Study: 31177984
Drug: Posterior limb
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior limb internal capsule involvement
Study: 31177984
Drug: Anterior limb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior limb internal capsule involvement
Study: 31177984
Drug: Anterior limb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior limb internal capsule lesions
Study: 23728047
Drug: Controller medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controller medicine
Study: 27914817
Drug: Quick relief
Normalized name: Capzasin Quick Relief
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quick relief medicine
Study: 27914817
Drug: Parental help
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental help with medications
Study: 27914817
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of medications
Study: 26435363
Drug: Daylight photodynamic
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daylight photodynamic therapy (DL‐PDT) with methyl aminolevulinate (MAL)
Study: 26435363
Drug: Conventional photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photodynamic therapy (c‐PDT) with methyl aminolevulinate (MAL)
Study: 19608845
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection (Group S): 30 mL of mepivacaine 1.5% injected posterior to the axillary artery
Study: 19608845
Drug: Triple injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple injections (Group T): 10 mL of mepivacaine 1.5% injected on the posterior, medial, and lateral aspects of the axillary artery
Study: 16448828
Drug: Placebo ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ultrasound treatment (inactivated device, 10 sessions of physiotherapy of 20 min each)
Study: 2286709
Drug: Haloperidol (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (fixed doses to achieve plasma levels above and below 18 ng/ml)
Study: 7028259
Drug: Initial low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial low-dose single-agent CCNU (CAMP postponed)
Study: 31998998
Drug: Expected treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expected treatment outcomes with knowledge of covariates
Study: 30176834
Drug: 30-min vigorous-intensity
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-min vigorous-intensity aerobic exercise session 24 hours prior to each anthracycline treatment
Study: 30176834
Drug: Prepared diet
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepared diet reduced to 50% of caloric needs for 48 hours prior to each anthracycline treatment
Study: 24508349
Drug: Elevated glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated glucose (>7.8 mmol/L)
Study: 19947986
Drug: Increased nocturnal
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Increased nocturnal oxygen flow rate (1 L more oxygen)
Study: 18762517
Drug: Cooling treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling treatment
Study: 10901709
Drug: Ifetroban (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifetroban (3 mg/kg in rats)
Study: 10901709
Drug: Ifetroban (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifetroban (1 mg/kg in dogs)
Study: 10901709
Drug: Ifetroban (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifetroban (1 mg/kg in monkeys)
Study: 10901709
Drug: Ifetroban (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifetroban (50 mg in humans)
Study: 12186623
Drug: One-week quadruple
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-week quadruple therapy (bismuth-based triple therapy plus a PPI or histamine receptor 2-blocker)
Study: 12186623
Drug: Furazolidone-based triple
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furazolidone-based triple therapy (furazolidone plus an antibiotic and a bismuth salt, a PPI or RBC)
Study: 12186623
Drug: Fluoroquinolone-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroquinolone-based triple therapy (levofloxacin or moxifloxacin plus an antibiotic and a PPI)
Study: 12186623
Drug: Ecabet sodium-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecabet sodium-based triple therapy (ecabet plus two antibiotics)
Study: 12186623
Drug: Rifabutin in
Normalized name: Product containing rifabutin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin in combination with a PPI and amoxycillin
Study: 16021868
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor (PI) regimen
Study: 8924308
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide with EMLA cream
Study: 8924308
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide with intradermal lidocaine
Study: 7523772
Drug: Cilazapril 5
Normalized name: cilazapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 5 mg b.i.d.
Study: 25273893
Drug: Active T-PEMF
Normalized name: t-plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active T-PEMF (one daily dose)
Study: 25273893
Drug: Active T-PEMF
Normalized name: t-plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active T-PEMF (two daily doses)
Study: 25273893
Drug: Placebo T-PEMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo T-PEMF (one daily dose)
Study: 24384592
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tenofovir (TDF) and emtricitabine/tenofovir (FTC/TDF) PrEP
Study: 17014550
Drug: High-volume haemofiltration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume haemofiltration (HVHF) at 6 L/h
Study: 17014550
Drug: Continuous venovenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous venovenous haemofiltration (CVVH) at 2 L/h
Study: 11020900
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate infusion at a dose of 100 mg/hr for 7 days
Study: 9540058
Drug: Oral tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tamoxifen (TAM) at doses of 40, 80 or 120 mg/day
Study: 9540058
Drug: Surgery, radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery, radiotherapy (4500-6000 cGy), and carboplatin (CBDCA; dose of 450-600 mg/m2)
Study: 7800587
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (12 grams daily, 3.6 g of EPA and DHA) for 3 weeks
Study: 7800587
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (12 grams daily) for 3 weeks
Study: 7800587
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (12 grams daily) for 6 weeks (in 9 patients)
Study: 3388151
Drug: Diltiazem (DTZ)
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem (DTZ) 90 mg twice daily, increased to 180 mg if non-responders after 8 weeks
Study: 3388151
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 25 mg once daily, increased to 50 mg if non-responders after 8 weeks
Study: 29311135
Drug: BMS‐823778 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐823778 (single and multiple ascending doses)
Study: 29311135
Drug: BMS‐823778 (pharmacokinetics)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐823778 (pharmacokinetics)
Study: 22723267
Drug: rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rosiglitazone (RSG) 4 mg b.i.d
Study: 10204379
Drug: Acupuncture treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatments in addition to non-steroidal anti-inflammatory drugs and intraarticular administration of glucocorticosteroids and inhibitors of proteases
Study: 10204379
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs together with intraarticular administration of glucocorticosteroids and inhibitors of proteases
Study: 28095046
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin D3 1,800 IU
Study: 25524395
Drug: Time framed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time framed as dates (e.g., June 1st, 2015)
Study: 25524395
Drug: Time framed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time framed as days (e.g., 5000 days)
Study: 23748948
Drug: Silver zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver zinc sulfadiazine with added sericin cream
Study: 23748948
Drug: Silver zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver zinc sulfadiazine cream (control)
Study: 21880194
Drug: bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: bovine lactoferrin (bLF) 70 mg/day
Study: 17845952
Drug: Clinical pathway
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pathway for managing UTIs in LTCFs, including decision tools for urine culture and antibiotic treatment initiation.
Study: 9533468
Drug: Cefixime suspension
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime suspension 8 mg/kg/day bd for 10 days
Study: 9533468
Drug: Co-amoxiclav suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav suspension 80 mg/kg/day tds for 10 days
Study: 7914121
Drug: Proxodolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxodolol 40 mg
Study: 7914121
Drug: Proxodolol 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxodolol 80 mg
Study: 620480
Drug: Cyproheptadine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (up to 42 mg/day)
Study: 28919011
Drug: Dabrafenib plus
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib plus trametinib (oral dabrafenib 150 mg twice per day plus oral trametinib 2 mg once per day)
Study: 25553889
Drug: Brodalumab 140
Normalized name: brodalumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 140 mg every 2 weeks
Study: 25553889
Drug: Brodalumab (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab (doses unspecified)
Study: 22267018
Drug: Oral tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tenofovir and emtricitabine/tenofovir PrEP
Study: 2652168
Drug: Cocaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (40 mg) with haloperidol (8 mg) pretreatment
Study: 2652168
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with haloperidol (8 mg) pretreatment
Study: 2652168
Drug: Cocaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (40 mg) with placebo pretreatment
Study: 728284
Drug: Intravenous disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous disopyramide (2 mg/kg)
Study: 728284
Drug: Oral disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disopyramide (Rythmodan and Norpace, 300 mg)
Study: 22167437
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation with local anesthesia (sedation group, n = 123)
Study: 19209092
Drug: Hexavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent vaccine
Study: 15320685
Drug: Hormonal responses
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal responses (testosterone, sex hormone binding globulin, free androgen index)
Study: 9031463
Drug: RO-11 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO-11 at a dose of 7,500 anti-FXa i.u. (110 anti-FXa i.u./Kg)
Study: 9031463
Drug: RO-11 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO-11 at doses of 9,000 and 12,500 anti-FXa i.u.
Study: 9031463
Drug: RO-11 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO-11 (all doses)
Study: 8034236
Drug: Heparin (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (calcium heparin, 12,500 IU in 0.5 ml)
Study: 31352853
Drug: SQ tree
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ tree sublingual immunotherapy (SLIT)-tablet
Study: 30279504
Drug: Atorvastatin 10mg/fenofibric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10mg/fenofibric acid 135mg for 12 weeks
Study: 30279504
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20mg for 12 weeks
Study: 18521047
Drug: Unopposed estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed estrogen (conjugated estrogens 0.625 mg)
Study: 18521047
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus 2.5 mg of medroxyprogesterone acetate
Study: 7586303
Drug: Sulotroban (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulotroban (800 mg QID)
Study: 1425867
Drug: Theophylline (Th)
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline (Th) 450-900 mg in the evening
Study: 2253659
Drug: Terbutaline (Te)
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline (Te) 7.5 mg twice daily
Study: 28809989
Drug: Calcipotriene 0.005%
Normalized name: CALCIPOTRIENE 0.005% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% topical suspension (Taclonex® TS)
Study: 28809989
Drug: Betamethasone Dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone Dipropionate 0.05% lotion (Diprosone®)
Study: 22537100
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone ER 16 mg
Study: 10550565
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B (test formulation)
Study: 10550565
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (reference formulation)
Study: 2064484
Drug: Standard behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavior therapy program
Study: 6225396
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin (0.5 to 1.0 mg/kg/day)
Study: 26684150
Drug: rhPTH(1‐84) 50
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhPTH(1‐84) 50 μg/day, escalated to 75 and then to 100 μg/day if needed
Study: 19160156
Drug: FAPC for
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAPC for additional treatment of bleeding from the main gastroepiploic artery via TGA
Study: 19160156
Drug: FAPC for
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAPC for additional treatment of bleeding from the main gastroepiploic artery via TVA
Study: 15723023
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with MDD and concurrent SUD symptoms
Study: 15723023
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without concurrent SUD symptoms
Study: 12572379
Drug: Jietongyin Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jietongyin Lotion (JTYL)
Study: 12572379
Drug: Rishu an
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rishu an Lotion (Control)
Study: 17339867
Drug: Tolterodine 4
Normalized name: tolterodine 4 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 4 mg twice daily
Study: 9467475
Drug: Tolterodine dosages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine dosages of ≤ 2 mg
Study: 1978372
Drug: Ipsapirone at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone at 7.5 mg t.i.d. for 4 weeks
Study: 356239
Drug: Proquazone (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proquazone (900 mg)
Study: 356239
Drug: Ibuprofen (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1200 mg)
Study: 27481207
Drug: Abatacept (CTLA4-Ig)
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept (CTLA4-Ig) administered via monthly intravenous infusions for 24 weeks, switched to placebo at 28 weeks, final dose at 52 weeks.
Study: 27481207
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via monthly intravenous infusions for 24 weeks, switched to abatacept at 28 weeks, final dose at 52 weeks.
Study: 25841032
Drug: Inhaled dihydroergotamine
Normalized name: dihydroergotamine Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dihydroergotamine (DHE)
Study: 16855921
Drug: Nabilone (1/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (1/4 - 1 mg/day)
Study: 10885439
Drug: UVA irradiation
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA irradiation (70% of the individual's predetermined minimal phototoxic dose)
Study: 8967586
Drug: Ropivacaine 0.5%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5%, 3 ml (15 mg)
Study: 8967586
Drug: Ropivacaine 0.75%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75%, 3 ml (22.5 mg)
Study: 1457358
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (20 mg d-1)
Study: 30266608
Drug: Stratified medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified medical therapy (intervention group)
Study: 20660670
Drug: Caspofungin (CAS)
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caspofungin (CAS) 50 mg/day; day 1, 70 mg
Study: 20660670
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (LAMB) 3 mg/kg of body weight/day
Study: 20660670
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CAS and LAMB (CASLAMB)
Study: 16363196
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg plus 2 g/day chitosan in two divided doses
Study: 16363196
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg plus placebo
Study: 7956214
Drug: Desogestrel-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel-containing oral contraceptive (9-week on, 1-week off regimen)
Study: 7956214
Drug: Desogestrel-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel-containing oral contraceptive (traditional regimen)
Study: 7956214
Drug: Desogestrel-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel-containing oral contraceptive (both regimens)
Study: 3575253
Drug: Theophylline-sodium-glycinate solution
Normalized name: Theophylline Sodium Glycinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline-sodium-glycinate solution administered orally after a standard breakfast (5.6 mg/kg body weight)
Study: 3575253
Drug: Theophylline-sodium-glycinate solution
Normalized name: Theophylline Sodium Glycinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline-sodium-glycinate solution administered orally on an empty stomach (5.6 mg/kg body weight)
Study: 3575253
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of theophylline-sodium-glycinate solution under fasting conditions
Study: 3575253
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of theophylline-sodium-glycinate solution
Study: 26218762
Drug: HF10 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HF10 therapy
Study: 26568428
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4 then 200 mg every 2 weeks (Q2W)
Study: 20799592
Drug: silymarin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: silymarin (70 mg x 3/day)
Study: 16806096
Drug: Atomoxetine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (titrated to a maximum dose of 1.8 mg/kg/day) administered once daily for up to 7 weeks